Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cord blood transplant method aims to beat High-Risk blood cancers

NCT ID NCT05884333

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 29 times

Summary

This study tests an improved method for cord blood transplants in adults with hard-to-treat blood cancers like leukemia and lymphoma. The approach uses a standard set of steps—including chemotherapy, radiation, and careful follow-up—to help the body accept the new stem cells. Researchers will track how well patients survive, how quickly their immune system recovers, and any side effects like graft-versus-host disease. The goal is to see if this optimized process leads to better outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA (AML) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.